Left Ventricular Strain: A Reliable Predictor of Short-Term Outcomes in Patients with Anterior Wall Myocardial Infarction without Heart Failure

Abstract

Background: Left ventricular ejection fraction (LVEF) is a key determinant in decision-making after acute myocardial infarction (MI). Little is known of its relationship with left ventricular Strain and N-Terminal fragment of pro-B-type Natriuretic Peptide (NT-pro-BNP) following acute anterior wall MI (AWMI).

Materials and Methods: We conducted a prospective cohort study of patients with a diagnosis of acute AWMI and the absence of overt heart failure (HF). Assessment of LVEF, strain parameters on echocardiography was done, and NT-pro-BNP levels were obtained. Follow-up for adverse cardiac events was done for 30 days postdischarge. Correlation of LVEF and NT-pro-BNP with various strain parameters were ascertained. Results: Of the total of 50 patients of AWMI enrolled, the mean LVEF in the study was 43.46 ± 3.72%. Eleven patients (22%) had adverse events at 30 days of follow-up. Patients with adverse events had significantly higher overall peak systolic longitudinal strain (PSLS), lower mid-region peak systolic longitudinal velocity (PSLV), and basal region PSLV. A significant negative correlation was observed between LVEF and mean Peak PSLS of combined apical plus mid regions of the left ventricle (r = −0.700). Log10-NT-pro BNP also showed a strong negative correlation with overall PSLV (r = −0.792) as well as regional PSLV values of combined apical plus mid (r = −0.763) and basal segments (r = −0.748). Conclusions: In patients with AWMI without HF, PSLS and PSLV are good predictors of adverse outcomes at 30-day follow-up. Furthermore, NT-pro BNP can also be an indirect predictor of strain parameters on echocardiography.

Keywords: Echocardiography, heart failure, left ventricular strain, natriuretic peptides, peak systolic longitudinal velocity

Introduction

ST-elevation myocardial infarctions (STEMI) impose huge morbidity and mortality burden on health systems.[1] Among them, acute anterior wall MI (AWMI’s) are known to have poorer outcomes both in terms of in-hospital mortality and long-term survival. Therefore, risk assessment of these patients is of paramount clinical importance, both from management as well as prognostic point of view. Currently, risk stratification of MI is based primarily on clinical history, electrocardiography changes, biochemical markers of myocardial injury, and echocardiographic assessment.

The N-terminal fragment of pro-B-type Natriuretic Peptide (NT-pro-BNP) has been studied extensively as a biomarker of severity and outcome of heart failure (HF) and mortality associated with acute myocardial infarction (AMI).[2,3] Secreted predominantly from the ventricular cardiomyocytes in response to increased wall tension, NT-proBNP is significantly increased after AMI and is an independent predictor of survival over the next 2 years.[4,5] Plasma NT-proBNP levels increase with age and have an inverse correlation with left ventricular ejection fraction (LVEF) with a negative predictive value of 98% in identifying LVEF ≤40%.[6] However, routine measurement of NT-proBNP has yet to be incorporated into the guidelines for the acute coronary syndrome (ACS). Some studies have even demonstrated that NT-proBNP measured at the time of hospitalization for MI tends to correlate with infarct size measured through magnetic resonance imaging on follow-up (for 4 and 12 months after AMI).[7,8] Measurement of myocardial strain and strain rate (SR) allows for the evaluation of myocardial deformation and hence the assessment of the systolic function...
of the ventricular myocardial fibers. Even subtle changes in the measurement of either is suggestive of myocardial dysfunction.\footnote{[9,10]} In fact, the longitudinal fibers in the sub-endocardial layer are very sensitive to ischemia and wall stress and thus can exhibit abnormal contractile features, even in the presence of an apparently normal LVEF.\footnote{[11]} Thus, longitudinal strain estimation through echocardiography allows for an early window, and hence, a more sensitive method of identifying subclinical LV systolic dysfunction compared to the traditional technique of LVEF, as assessed using Simpson’s method.\footnote{[12-14]} However, our knowledge regarding the relationship between these echocardiographic parameters and biochemical markers in patients without clinically apparent HF is limited.\footnote{[12,15-19]} Hence, we aim to establish a correlation between LVEF, LV strain parameters, and NT-pro BNP in patients of AWMI without clinically overt HF.

Materials and Methods

Study design

The present study was conducted at a tertiary care cardiology center in India. It was a prospective cohort study of 3 months duration, in which a total of 50 cases of AWMI were studied. AWMI patients were diagnosed as per the American College of Cardiology/American Heart Association for diagnosis and management of STEMI.\footnote{[11]} Patients admitted to the intensive coronary care unit with a diagnosis of AWMI <5 days old (irrespective of their revascularization status) and age <75 years were enrolled for inclusion. Written and informed consent were obtained from each subject. Patients with AWMI who had clinical signs and symptoms of overt HF such as basal rales raised jugular venous pressure, dyspnea, orthopnea, acute left ventricular (LV) failure and Killip class >2 were excluded. Also excluded were those AWMI patients with uncontrolled arrhythmias (bradyarrhythmia/tachyarrhythmia), prior ACS, structural heart diseases, renal failure, or any chronic debilitating conditions and those not giving consent. Following discharge from the hospital, the patients were then followed up over 30 days through scheduled outpatient department visits and telephonic updates to record the occurrence of any adverse cardiac events. The primary end-point (a composite of HF, MI, and death) was studied with respect to LVEF, NT-pro-BNP, and LV strain parameters. In addition, in group comparison of NT-ProBNP, LVEF, and LV strain parameters were done among those who had primary endpoint events on follow vis-à-vis those who did not. The study was approved by the Institutional Ethics Committee and funded under the Intramural Short-Term Medical Research Fellowship program, conducted by the Research Cell, KGMU.

NT-pro BNP measurement

Peripheral samples of plasma were obtained within 24 h of echocardiographic assessment. Measurement and quantitative analysis of NT-pro BNP were performed on the commercially available COBAS e 411 immunoassay analyzer, immediately after blood sampling.

Standardized normal values as defined by COBAS for Elecsys® NT-proBNP are shown in Figure 1.

Echocardiographic assessment

Two-dimensional M-mode and tissue Doppler echocardiographic examinations were performed within 24 h of admission on all participants. The echocardiographic data were acquired with a commercially available digital ultrasound machine (Vivid 7, Vingmed; GE Healthcare, Horten, Norway) using a 3.5-MHz phased array transducer. The measurements were made according to previously published guidelines.\footnote{[20]} Three heart cycles of the apical 4-, 3-, and 2-chamber views were captured in conventional two-dimensional and color tissue Doppler modes. The frame rate was >100/s for Tissue Doppler imaging. Seventeen segments of the LV were used for all analyses. Offline analysis was conducted by an expert cardiologist. In the anteroseptal wall of the LV, the basal, mid, and apical regions were subjected to measurement of the peak systolic longitudinal velocities (PSLV) (cm/s). Then, the peak systolic longitudinal strain (PSLS) (%) and the PSLS rates (PSLSR) (s^-1) were calculated. Finally, the mean PSLV, PSLS, and PSLSR of the three regions were calculated to be used in the study.

The LVEF was assessed by the biplane Simpson’s rule.

Statistical analysis

Data were analyzed using the Statistical Package for the Social Sciences (SPSS) version 20.0 (SPSS Inc., Chicago, IL, USA). Independent samples t-test was used to compare the data between groups. Correlation of different continuous parameters was studied using the Pearson correlation coefficient. Receiver-operator curve analysis was performed to deduce a cutoff value of different parameters showing significant association with adverse cardiac events. A P < 0.05 was considered to indicate a statistically significant association.

Results

For the 50 patients included in the study, the age of patients ranged from 28 to 71 years, with the mean age being 52.36 ± 9.70 years. Most of the patients (92%) were 52.36 ± 9.70 years. Most of the patients (92%)

![Figure 1: Age standardized normal and abnormal values of NT-pro BNP](image)
were male. LVEF values ranged from 37% to 58%, with a mean value of 43.46 ± 3.72%. NT-proBNP values had a wide range starting from 288.6 to 31,843 pg/ml, thereby showing a highly skewed distribution. To address this issue, instead of absolute values of NT-proBNP, logarithmic scale \( \log_{10} \) values of NT-proBNP were calculated, which were confined to a rather narrow range starting from 2.46 to 4.50 and a mean value of 3.51 ± 0.55. The distribution of \( \log_{10} \) NT-proBNP values was rather normalized. While calculating average values for all three segments together, PSLV ranged from 0.53 to 5.28 m/s with a mean value of 2.41 ± 1.02 m/s, PSLS values ranged from −22.53 to −1.84% with a mean value of −10.27 ± 4.59%, while PSLSR ranged from −1.31 to −0.08/s with a mean value of −0.80 ± 0.27/s.

However, when taking the apical and mid segments together, PSLV values ranged from 0.22 to 4.25 m/s with a mean of 1.83 ± 0.93 m/s, PSLS values ranged from −16.75 to −0.85% with a mean of −6.87 ± 3.66% and PSLSR values ranged from −1.15 to 0.80/s with a mean of −0.53 ± 0.30/s. On the other hand, for the basal segment alone, PSLV values ranged from 1.15 to 7.34 m/s with a mean of 3.37 ± 1.37 m/s, PSLS values ranged from −36.10 to −3.10% with a mean of −17.06 ± 7.94% and PSLSR values ranged from −3.04 to −0.45/s with a mean of −1.34 ± 0.55/s [Table 1].

Post 30-day follow up, out of 50 subjects included in the study, 39 (78%) did not experience any adverse cardiac event. Of the remaining 11 (22%), there were seven repeat hospitalizations (5 for HF and 2 for MI) and 4 deaths.

The mean age of patients suffering adverse events was significantly higher (59.82 ± 7.28 years) as compared to that of patients who did not experience an adverse event (50.26 ± 9.31 years) \((P = 0.003)\). Patients experiencing adverse cardiac events had significantly lower mean LVEF \((P < 0.001)\) and PSLV \((P = 0.002)\) and higher mean \(\log_{10}\) NT-proBNP \((P < 0.001)\) values as compared to those who remained event-free during the 30-day follow-up. Mean PSLS and PSLSR values were also more negative in the event free group; however, the difference was statistically significant only for PSLS \((P = 0.002)\) [Table 2].

Among mid-segment parameters, PSLV was found to be significantly lower in patients with adverse events as compared to those not having adverse events \((P = 0.005)\), whereas mean PSLS was significantly higher in cases having adverse events as compared to those not having adverse events \((P < 0.001)\). There was no significant difference between the two groups with respect to PSLSR. Similar to mid-segment parameters, for the basal segment too, PSLV value was significantly lower in cases having adverse events as compared to those not having adverse events, whereas PSLS was significantly higher (less negative) in cases having adverse events as compared to those not having adverse events. No statistically significant difference was observed between the two groups with respect to PSLSR [Table 3].

Correlation between the various variables was calculated and a strong negative correlation was observed between LVEF with apical + mid PSLS \((r = 0.700)\), \(\log_{10}\) NT-proBNP with PSLV \((r = 0.792)\), apical + mid PSLV \((r = 0.763)\), and basal PSLV \((r = 0.748)\). While a strong positive correlation was found to exist between \(\log_{10}\) NT-proBNP with PSLS \((r = 0.700)\) and apical + mid PSLV \((r = 0.778)\) [Figure 2].

The receiver operating characteristic curves were constructed to determine the optimal cutoff values for the parameters included in our study at predicting clinical events at the end of 1 month.

For different parameters being evaluated, \(\log_{10}\) NT-proBNP and LVEF had the maximum area under curve (AUC) values (0.904 and 0.939), whereas age had minimum AUC (0.789). For LVEF, underbalanced considerations, a cut-off value < 42.5 was projected to be 90.9% sensitive and 76.9% specific whereas for \(\log_{10}\) NT-proBNP under balanced considerations, a cut-off value > 3.78 was 90.9% sensitive and 87.2% specific. For PSLV and PSLS under balanced considerations, the cut-off values ≤ 1.875 and ≤ 8.867 had a sensitivity of 81.8% and specificity of 82.1% and 79.5%, respectively. For the apical + midsegments together, under balanced conditions, the sensitivity value was 81.8% for both PSLV as well as PSLS, whereas specificity value was 69.2% for PSLV and

### Table 1: Baseline study parameters of the patients enrolled in the study \((n=50)\)

| Characteristic       | Mean±SD (range) |
|----------------------|-----------------|
| Age (years)          | 52.36±9.70 (28-71) |
| Gender, n (%)        |                 |
| Male                 | 46 (92.0)       |
| Female               | 4 (8.0)         |
| LVEF (%)             | 43.46±3.72 (37-58) |
| \(\log_{10}\) NT-proBNP | 3.51±0.55 (2.46-4.50) |
| PSLV (m/s)           | 2.41±1.02 (0.53-5.28) |
| PSLS (%)             | −10.27±4.59 (−22.53−1.84) |
| PSLSR (/s)           | −0.80±0.27 (−1.31-0.08) |
| Apical + mid PSLV (m/s) | 1.93±0.93 (0.22-4.25) |
| Apical + mid PSLS (%) | −6.87±3.65 (−16.86−0.85) |
| Apical + mid PSLSR (/s) | −0.53±0.30 (−1.15-0.80) |
| Basal PSLV (m/s)     | 3.37±1.36 (1.15-7.34) |
| Basal PSLS (%)       | −17.06±7.94 (−36.10−3.10) |
| Basal PSLSR (/s)     | −1.34±0.55 (−3.04-0.45) |

LVEF: Left ventricular ejection fraction, NT-proBNP: N-terminal fragment of pro-B-type natriuretic peptide, PSLV: Peak systolic longitudinal velocities, PSLS: Peak systolic longitudinal strain, PSLSR: Peak systolic longitudinal strain rate, SD: Standard deviation
Table 2: Comparison of baseline study parameters between patients experiencing adverse cardiac events and those not experiencing adverse events

| Parameter                  | Mean±SD      | Statistical significance |
|----------------------------|--------------|--------------------------|
|                           | Adverse cardiac event (n=11) | No adverse cardiac event (n=39) | t    | P     |
| Age                       | 59.82±7.28   | 50.26±9.31              | 3.137 | 0.003 |
| LVEF                      | 39.82±2.14   | 44.49±3.42              | −4.274 | <0.001|
| Log_{10} NT-proBNP        | 4.17±0.27    | 3.32±0.46               | 5.859 | <0.001|
| PSLV                      | 1.57±0.60    | 2.64±1.00               | −3.367 | 0.002 |
| PSLS                      | −6.60±2.65   | −11.30±4.51             | 3.283 | 0.002 |
| PSLSR                     | −0.67±0.18   | −0.84±0.29              | 1.844 | 0.071 |
| Apical + mid PSLV         | 1.25±0.61    | 2.12±0.91               | −2.936 | 0.005 |
| Apical + mid PSLS         | −3.58±2.00   | −7.80±3.49              | 3.831 | <0.001|
| Apical + mid PSLSR        | −0.46±0.21   | −0.55±0.32              | 0.890 | 0.378 |
| Basal PSLV                | 2.21±0.69    | 3.69±1.34               | −3.528 | 0.001 |
| Basal PSLS                | −12.66±5.16  | −18.30±8.19             | 2.156 | 0.036 |
| Basal PSLSR               | −1.09±0.37   | −1.42±0.58              | 1.753 | 0.086 |

Baseline study parameters of the two groups were compared using independent t-test. LVEF: Left ventricular ejection fraction, NT-proBNP: N-terminal fragment of pro B-type natriuretic peptide, PSLV: Peak systolic longitudinal velocities, PSLS: Peak systolic longitudinal strain, PSLSR: Peak systolic longitudinal strain rate, SD: Standard deviation

Table 3: Receiver-operator curve analysis for deducing cutoff values of different study parameters* for prediction of adverse cardiac event

| Parameter          | AUC    | Consideration | Cut-off value | Predicted Sensitivity (%) | Predicted Specificity (%) |
|--------------------|--------|---------------|---------------|---------------------------|----------------------------|
| Age                | 0.789  | High sensitivity | ≥51.0         | 81.8                      | 56.4                       |
|                    |        | High specificity | ≥59.0         | 36.4                      | 82.1                       |
|                    |        | Balanced        | ≥54.5         | 63.6                      | 61.5                       |
| LVEF               | 0.904  | High sensitivity | ≤43.5         | 100                       | 64.1                       |
|                    |        | High specificity | ≤41.5         | 72.7                      | 87.2                       |
|                    |        | Balanced        | ≤42.5         | 90.9                      | 76.9                       |
| Log_{10} NT-proBNP | 0.939  | High sensitivity | ≥3.73         | 100.0                     | 84.6                       |
|                    |        | High specificity | ≥4.01         | 72.7                      | 94.9                       |
|                    |        | Balanced        | ≥3.78         | 90.9                      | 87.2                       |
| PSLV               | 0.834  | High sensitivity | ≤2.785        | 90.9                      | 43.6                       |
|                    |        | High specificity | ≤1.688        | 72.7                      | 87.2                       |
|                    |        | Balanced        | ≤1.875        | 81.8                      | 82.1                       |
| PSLS               | 0.851  | High sensitivity | ≤−7.283       | 45.5                      | 84.6                       |
|                    |        | Balanced        | ≤−8.867       | 81.8                      | 79.5                       |
| Apical + mid PSLV  | 0.766  | High sensitivity | ≤1.575        | 90.9                      | 64.1                       |
|                    |        | High specificity | ≤1.110        | 36.4                      | 92.3                       |
|                    |        | Balanced        | ≤1.520        | 81.8                      | 69.2                       |
| Apical + mid PSLS  | 0.858  | High sensitivity | ≥−6.35        | 100.0                     | 66.7                       |
|                    |        | High specificity | ≥−3.88        | 54.5                      | 87.2                       |
|                    |        | Balanced        | ≥−5.90        | 81.8                      | 74.4                       |
| Basal PSLV         | 0.848  | High sensitivity | ≤3.24         | 100.0                     | 66.7                       |
|                    |        | High specificity | ≤2.54         | 72.7                      | 84.6                       |
|                    |        | Balanced        | ≤2.825        | 81.8                      | 76.9                       |
| Basal PSLS         | 0.717  | High sensitivity | ≥−19.95       | 100.0                     | 43.6                       |
|                    |        | High specificity | ≥−13.00       | 54.5                      | 76.9                       |
|                    |        | Balanced        | ≥−15.35       | 72.7                      | 61.5                       |

*Only those parameters were included that had shown a significant association with adverse event. LVEF: Left ventricular ejection fraction, NT-proBNP: N-terminal fragment of pro B-type natriuretic peptide, PSLV: Peak systolic longitudinal velocities, PSLS: Peak systolic longitudinal strain, PSLSR: Peak systolic longitudinal strain rate, AUC: Area under curve

74.4% for PSLV and PSLS, under balanced conditions, sensitivity was 81.8% and 72.7%, respectively, whereas specificity was 76.9% and 61.5%, respectively [Figure 3].
Discussion

Our study demonstrated that the longitudinal strain (expressed as PSLV and PSLS) has a significantly stronger relationship to increased cardiac wall stress (expressed as a rise in levels of NT-pro BNP) than LVEF, which rather has a moderately significant correlation, in patients of AWMI without HF.

While most studies done in the past used global longitudinal strain (GLS) for the assessment of myocardial longitudinal function, our study instead utilizes the mean of longitudinal strain measures of the three individuals (basal, mid, and apical) segments. The relationship between Longitudinal Strain and B-type natriuretic peptide has been described previously by various authors.[19,21-24] An echocardiographic sub-study of the VALIANT trial has revealed that longitudinal strain correlates with prognosis (all-cause mortality) independent of LVEF.[25] In a large community based cohort study, a significant correlation was found between PSLV (measured by TDI) and NT-pro BNP levels.[24] These findings were confirmed in a smaller cohort of patients with suspected HF, where longitudinal velocity predicted BNP and subsequently, a diagnosis of HF.[27] Hence, the results of our study do show concordance with previous studies, with respect to the point that longitudinal strain is a more reliable predictor of NT-proBNP levels and hence wall stress than LVEF.

A potential explanation for the above-mentioned results can be attributed to the point that myocardial strain assessment will predict early myocardial dysfunction (of subendocardial layers) in contrast to a fall in LVEF, which comparatively appears to be a cruder marker. Hence, it will provide an early window for optimization of therapy before frank HF sets in. There is also rapid induction of BNP gene expression in the surrounding nonischemic myocardium, in addition to the peri-infarct zone, which has been demonstrated in animal experiments.[27] LVEF rather tends to have poor sensitivity in reflecting the function of these areas. Hence, it is less accurate in detecting the wall stress in the subendocardial layers of LV. These findings, along with the fact that subendocardial longitudinal fibers are especially sensitive to ischemia,[11] lend explanatory support to the findings in our study.

While comparing the different parameters between the cases experiencing adverse cardiac events and the event-free group, LVEF and mean PSLV were found to be significantly lower in the cases with adverse cardiac events, whereas NT-proBNP and mean PSLS were found to be significantly higher. The information obtained on analyzing strain parameters of basal, mid, and apical regions separately was comparable to that obtained by average strain readings in
our study. Hence, segmental analysis for the strain pattern of LV may not be of any additional benefit. In the present prospective study, apart from NT-proBNP and LVEF, which have emerged as good predictors, we also have been able to demonstrate PSLS as an independent predictor of adverse cardiac events (hospitalization for MI or worsening HF and death). However, standardization of these values requires larger studies.

**Study limitations**

Our study was limited by a small sample size and a shorter follow-up. Inclusion of revascularization status of patients and repeat strain analysis on follow-up would have been more informative. Because, our enrollment was restricted to de novo cases of AWMI, our echocardiographic assessment was confined to anteroseptal wall of LV. Silent infarctions in other territories could have led to LVEF alterations, but since the population was relatively young, the contributions are less likely but cannot be ruled out. Owing to the relatively broad range of LVEF in the study, further research with a larger sample size could throw light on the consistent correlation of GLS and adverse outcomes in various subgroups of LVEF. The use of tissue Doppler imaging for the computation of strain is subject to high operator variability. Speckle tracking echocardiography, which offers angle independent analysis of tissue motion deformation, is a more superior technique.[28,29]

**Conclusions**

Apart from NT-proBNP and LVEF, PSLS, and PSLV are good predictors of adverse outcomes at 30-day follow-up and may further contribute to risk stratification of these patients, especially by providing an early window for intervention. Furthermore, aside from being a good prognostic marker, NT-proBNP can also be used as an indirect predictor of myocardial longitudinal strain and velocity. Larger long-term studies are required to validate these findings.

**Acknowledgment**

Grant support was provided under the Intramural Short-Term Medical Research Fellowship program of King George's Medical University, Lucknow, Uttar Pradesh, India.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr., Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78-140.
2. Munagala VK, Burnett JC Jr, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004;29:707-69.
3. Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P, et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 2005;294:2866-71.
4. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786-92.
5. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921-9.
6. Bay M, Kirk V, Parner J, Hassager C, Nielsen H, Krogsgaard K, et al. NT-proBNP: A new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 2003;89:150-4.
7. Mayr A, Mair J, Schocke M, Klug G, Pedarmig K, Haubner BJ, et al. Predictive value of NT-pro BNP after acute myocardial infarction: Relation with acute and chronic infarct size and myocardial function. Int J Cardiol 2011;147:118-23.
8. Bruder O, Jensen C, Jochims M, Farazandeh M, Barkhausen J, Schlosser T, et al. Relation of B-type natriuretic peptide (BNP) and infarct size as assessed by contrast-enhanced MRI. Int J Cardiol 2010;144:53-8.
9. Yingchoncharoen T, Agarwal S, Popovic ZB, Marwick TH. Normal ranges of left ventricular strain: A meta-analysis. J Am Soc Echocardiogr 2013;26:185-91.
10. Cho GY, Marwick TH, Kim HS, Kim MK, Hong KS, Oh DJ. Global 2-dimensional strain as a new prognosticator in patients with heart failure. J Am Coll Cardiol 2009;54:618-24.
11. Zoroufian A, Razmi T, Taghavi-Shavazi M, Lotti-Tokaldany M, Jalali A. Evaluation of subclinical left ventricular dysfunction in diabetic patients: Longitudinal strain velocities and left ventricular dysynchrony by twodimensional speckle tracking echocardiography study. Echocardiography 2014;31:456-63.
12. Vinereanu D, Lim PO, Freneaux MP, Fraser AG. Reduced myocardial velocities of left ventricular long-axis contraction identify both systolic and diastolic heart failure-a comparison with brain natriuretic peptide. Eur J Heart Fail 2005;7:512-9.
13. Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: Comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging 2009;2:356-64.
14. Liu YW, Tsai WC, Su CT, Lin CC, Chen JH. Evidence of left ventricular systolic dysfunction detected by automated function imaging in patients with heart failure and preserved left ventricular ejection fraction. J Card Fail 2009;15:782-9.
15. Kalam K, Othahal P, Marwick TH. Prognostic implications of global LV dysfunction: A systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart 2014;100:1673-80.
16. Maisel A, Mueller C, Adams K, Jr, Anker SD, Aspromonte N, Cleland JG, Cohen-Solal A, et al. State of the art: Using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824-39.
17. Fazlinezhad A, Rezaeian MK, Yousefzadeh H, Ghaffarzadegan K, Khajedalu M. Plasma brain natriuretic peptide (BNP) as
Singh, et al.: Post MI LV strain predicts short term outcomes

an indicator of left ventricular function, early outcome and mechanical complications after acute myocardial infarction. Clin Med Insights Cardiol 2011;5:77-83.

18. De Vecchis R, Esposito C, Cantatrione S. Natriuretic peptide-guided therapy: Further research required for still-unresolved issues. Herz 2013;38:618-28.

19. Yoneyama A, Koyama J, Tomita T, Kumazaki S, Tsutsui H, Watanabe N, et al. Relationship of plasma brain-type natriuretic peptide levels to left ventricular longitudinal function in patients with congestive heart failure assessed by strain Doppler imaging. Int J Cardiol 2008;130:56-63.

20. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.

21. Uraizee I, Cheng S, Hung CL, Verma A, Thomas JD, Zile MR, et al. Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease. Am J Hypertens 2013;26:1234-41.

22. Motoki H, Borowski AG, Shrestha K, Troughton RW, Tang WH, Thomas JD, et al. Incremental prognostic value of assessing left ventricular myocardial mechanics in patients with chronic systolic heart failure. J Am Coll Cardiol 2012;60:2074-81.

23. Ersbøll M, Valeur N, Mogensen UM, Andersen M, Greibe R, Møller JE, et al. Global left ventricular longitudinal strain is closely associated with increased neurohormonal activation after acute myocardial infarction in patients with both reduced and preserved ejection fraction: A two-dimensional speckle tracking study. Eur J Heart Fail 2012;14:1121-9.

24. Ersbøll M, Valeur N, Mogensen UM, Andersen MJ, Møller JE, Hassager C, et al. Relationship between left ventricular longitudinal deformation and clinical heart failure during admission for acute myocardial infarction: A two-dimensional speckle-tracking study. J Am Soc Echocardiogr 2012;25:1280-9.

25. Hung CL, Verma A, Uno H, Shin SH, Bourgoun M, Hassanein AH, et al. Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol 2010;56:1812-22.

26. Mogelvang R, Goetze JP, Pedersen SA, Olsen NT, Marott JL, Schnohr P, et al. Preclinical systolic and diastolic dysfunction assessed by tissue Doppler imaging is associated with elevated plasma pro-B-type natriuretic peptide concentrations. J Card Fail 2009;15:489-95.

27. Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995;92:1558-64.

28. Mondillo S, Galderisi M, Mele D, Lomorella VS, Zaca V, Ballo P, et al. Speckle-tracking echocardiography a new technique for assessing myocardial function. J Ultrasound Med 2011;30:71-83.

29. Sitia S, Tomasoni L, Turiel M. Speckle tracking echocardiography: A new approach to myocardial function. World J Cardiol 2010;2:1-5.